<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="735">
  <stage>Registered</stage>
  <submitdate>11/09/2005</submitdate>
  <approvaldate>11/09/2005</approvaldate>
  <nctid>NCT00163761</nctid>
  <trial_identification>
    <studytitle>Efficacy Study of Outpatient Therapy for Lymphoma</studytitle>
    <scientifictitle>A Multicentre Phase II Study of Risk-adjusted Outpatient-based Salvage Therapy for Patients With Relapsed and Refractory Lymphoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>AH226/02</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non-Hodgkin's Lymphoma</healthcondition>
    <healthcondition>Hodgkin's Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Hodgkin's</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - gemcitabine, vinorelbine, ifosfamide, filgastrim
Treatment: drugs - gemcitabine, vinorelbine, filgastrim

Active Comparator: Commence VGF treatment - Drug. Vinorelbine, gemcitabine and filgrastim 21 day cycle

Active Comparator: Commence F-GIV treatment - Drug. Gemcitabine, ifosfamide, Vinorelbine and filgrastim 21 day cycle


Treatment: drugs: gemcitabine, vinorelbine, ifosfamide, filgastrim
Drug

Treatment: drugs: gemcitabine, vinorelbine, filgastrim
Drug

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate the efficacy (overall response rate) of a risk-adjusted outpatient-based approach to lymphoma salvage therapy with VGF (vinorelbine, gemcitabine and pegfilgrastim) and/or F-GIV (gemcitabine, Ifosfamide, vinorelbine and pegfilgrastim).</outcome>
      <timepoint>After two cycles and after four cycles</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate safety,</outcome>
      <timepoint>Days 1 and 8 for every cycle, days 10,12,14, and 16 for first cycle.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>relapse free survival,</outcome>
      <timepoint>After 2 cycles, 4 cyles and every 3 or 4 months for 12 months. Then every 6 months until disease progression</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>overall survival,</outcome>
      <timepoint>every 3 or 4 months for 12 months. Then every 6 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>and planned dose-on-time.</outcome>
      <timepoint>After two cycles and after four cycles</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  age &gt; 18 years

          -  relapsed or primary refractory non-Hodgkin's lymphoma (NHL) or Hodgkin's Disease (HD)

          -  ECOG 0 - 2

          -  written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Intention to proceed with any form of transplant therapy following fewer than 2 cycles
             of protocol salvage therapy

          -  bilirubin &gt; 50Âµmol/litre unless secondary to lymphoma

          -  creatinine &gt; 2 x upper limit of normal unless secondary to lymphoma, absolute
             neutrophil count &lt;0.5 x 109/litre and / or platelets &lt; 50 x 109/litre unless secondary
             to lymphoma

          -  relapse within 6 months of a prior transplant procedure (autologous or allogeneic)

          -  known sensitivity to E coli derived preparations</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>90</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,TAS,VIC,WA</recruitmentstate>
    <hospital>Canberra Hospital - Canberra</hospital>
    <hospital>Royal North Shore Hospital - Sydney</hospital>
    <hospital>Mater Adult Hospital - South Brisbane</hospital>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <hospital>The Royal Melbourne Hospital - Melbourne</hospital>
    <hospital>Frankston Hospital - Melbourne</hospital>
    <hospital>Monash Medical Centre - Melbourne</hospital>
    <hospital>Border Medical Oncology - Wodonga</hospital>
    <hospital>Fremantle Hospital - Fremantle</hospital>
    <postcode>2605 - Canberra</postcode>
    <postcode>2065 - Sydney</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>7001 - Hobart</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>3050 - Melbourne</postcode>
    <postcode>3199 - Melbourne</postcode>
    <postcode>3690 - Wodonga</postcode>
    <postcode>6160 - Fremantle</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Bayside Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase II trial evaluating the efficacy (overall response rate) of a risk-adjusted
      outpatient based approach to lymphoma salvage therapy with vinorelbine, gemcitabine and
      pegfilgrastim and/or gemcitabine, ifosfamide, vinorelbine and pegfilgrastim.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00163761</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andrew Spencer, Assoc. Prof</name>
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>